Skip to main content
Journal cover image

Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.

Journal articles  - Journal Article
Qin, X; Hakenjos, JM; MacKenzie, KR; Barzi, M; Chavan, H; Nyshadham, P; Wang, J; Jung, SY; Guner, JZ; Chen, S; Guo, L; Krishnamurthy, P ...
Published in: Drug Metab Dispos
February 2022

Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor, widely used for the treatment of major depressive disorder. Although DLX has shown good efficacy and safety, serious adverse effects (e.g., liver injury) have been reported. The mechanisms associated with DLX-induced toxicity remain elusive. Drug metabolism plays critical roles in drug safety and efficacy. However, the metabolic profile of DLX in mice is not available, although mice serve as commonly used animal models for mechanistic studies of drug-induced adverse effects. Our study revealed 39 DLX metabolites in human/mouse liver microsomes and mice. Of note, 13 metabolites are novel, including five N-acetyl cysteine adducts and one reduced glutathione (GSH) adduct associated with DLX. Additionally, the species differences of certain metabolites were observed between human and mouse liver microsomes. CYP1A2 and CYP2D6 are primary enzymes responsible for the formation of DLX metabolites in liver microsomes, including DLX-GSH adducts. In summary, a total of 39 DLX metabolites were identified, and species differences were noticed in vitro. The roles of CYP450s in DLX metabolite formation were also verified using human recombinant cytochrome P450 (P450) enzymes and corresponding chemical inhibitors. Further studies are warranted to address the exact role of DLX metabolism in its adverse effects in vitro (e.g., human primary hepatocytes) and in vivo (e.g., Cyp1a2-null mice). SIGNIFICANCE STATEMENT: This current study systematically investigated Duloxetine (DLX) metabolism and bioactivation in liver microsomes and mice. This study provided a global view of DLX metabolism and bioactivation in liver microsomes and mice, which are very valuable to further elucidate the mechanistic study of DLX-related adverse effects and drug-drug interaction from metabolic aspects.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Drug Metab Dispos

DOI

EISSN

1521-009X

Publication Date

February 2022

Volume

50

Issue

2

Start / End Page

128 / 139

Location

Netherlands

Related Subject Headings

  • Serotonin and Noradrenaline Reuptake Inhibitors
  • Serotonin
  • Pharmacology & Pharmacy
  • Microsomes, Liver
  • Mice
  • Major Depressive Disorder
  • Duloxetine Hydrochloride
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Qin, X., Hakenjos, J. M., MacKenzie, K. R., Barzi, M., Chavan, H., Nyshadham, P., … Li, F. (2022). Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice. Drug Metab Dispos, 50(2), 128–139. https://doi.org/10.1124/dmd.121.000633
Qin, Xuan, John M. Hakenjos, Kevin R. MacKenzie, Mercedes Barzi, Hemantkumar Chavan, Pranavanand Nyshadham, Jin Wang, et al. “Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.Drug Metab Dispos 50, no. 2 (February 2022): 128–39. https://doi.org/10.1124/dmd.121.000633.
Qin X, Hakenjos JM, MacKenzie KR, Barzi M, Chavan H, Nyshadham P, et al. Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice. Drug Metab Dispos. 2022 Feb;50(2):128–39.
Qin, Xuan, et al. “Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.Drug Metab Dispos, vol. 50, no. 2, Feb. 2022, pp. 128–39. Pubmed, doi:10.1124/dmd.121.000633.
Qin X, Hakenjos JM, MacKenzie KR, Barzi M, Chavan H, Nyshadham P, Wang J, Jung SY, Guner JZ, Chen S, Guo L, Krishnamurthy P, Bissig K-D, Palmer S, Matzuk MM, Li F. Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice. Drug Metab Dispos. 2022 Feb;50(2):128–139.
Journal cover image

Published In

Drug Metab Dispos

DOI

EISSN

1521-009X

Publication Date

February 2022

Volume

50

Issue

2

Start / End Page

128 / 139

Location

Netherlands

Related Subject Headings

  • Serotonin and Noradrenaline Reuptake Inhibitors
  • Serotonin
  • Pharmacology & Pharmacy
  • Microsomes, Liver
  • Mice
  • Major Depressive Disorder
  • Duloxetine Hydrochloride
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences